Onconetix SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Submission of matters to a vote of security holders · Financial statements and exhibits
AI summary, unreviewedOnconetix, Inc. shareholders approve reverse split authority (1-for-2 to 1-for-15) and Series F PIPE conversion shares at 2026 annual meeting
Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedOnconetix (ONCO) Effects 1-for-10 Reverse Stock Split, Cutting Shares Outstanding to About 670,000
Entry into a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedOnconetix amends Realbotix share exchange: Seller to own 95% of fully diluted shares if Net Cash is under $12.5 million; End Date extended to March 31, 2027
Other events · Financial statements and exhibits
AI summary, unreviewedOnconetix (ONCO) Announces Second 1-for-10 Reverse Split, Aggregate 1-for-100 Effective November 6, 2026
Other events · Financial statements and exhibits
AI summary, unreviewedOnconetix, Inc. Upsizes Realbotix Grid Note Draw to $3.0 Million Outstanding With $500,000 Advance
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
Entry into a material definitive agreement · Unregistered sales of equity securities · Financial statements and exhibits